Neoadjuvant immunotherapy with interferon of the spontaneously metastasizing murine B16F10L melanoma

✍ Scribed by Svetomir N. Markovic; Donna M. Murasko

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: French
• Weight: 919 KB
• Volume: 45
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910450435

✦ Synopsis

We have previously demonstrated that administration of interferon a/b (IFN) for 4-5 days after challenge with a transplantable Moloney sarcoma virus-induced tumor completely inhibited tumor development. In the present study, we examined the therapeutic effects of IFN on mortality induced by metastatic dissemination of the B 16F I OL murine melanoma. IFN was administered at various times in relation to the surgical removal of primary tumor: days -5 to -I prior to tumor excision (neo-adjuvant protocol), or for 5 days after tumor excision, beginning on days I, 6 or I I after excision of the primary tumor (adjuvant protocols). The neo-adjuvant protocol was superior to all other protocols, significantly increasing percentage survival (56% vs. 0%) and median survival time (>84 days M. 33 days) compared to untreated controls, as well as to all adjuvant protocols. In contrast, IFN treatment on days I to 5 after excision of the primary tumor decreased median survival time of cases compared to untreated controls (20 days vs. 33 days). Both IFN-induced inhibition and enhancement of metastatic dissemination were dose-dependent, with higher amounts of IFN producing greater inhibition or enhancement. The superior therapeutic efficacy of the neo-adjuvant IFN treatment was associated with increased spleen and lung-derived natural killer cell cytolytic activity (on days -4,O and 2) followed by a later (day 13) increase in lung-associated cytolytic T-cell responses.